MUC1*-Targeted CAR T
Solid Tumors (e.g., Breast, Lung, Ovarian, Pancreatic)
Pre-clinicalActive
Key Facts
Indication
Solid Tumors (e.g., Breast, Lung, Ovarian, Pancreatic)
Phase
Pre-clinical
Status
Active
Company
About Minerva Biotechnologies
Minerva Biotechnologies is a clinical-stage biotech targeting a foundational oncology target, MUC1*, present on approximately 80% of solid tumors. Its lead programs include MUC1*-targeted CAR T-cell therapies and antibody-drug conjugates (ADCs) for cancers like breast, lung, ovarian, and pancreatic. In parallel, the company has leveraged its discoveries in stem cell biology to develop the AlphaSTEM® platform, aimed at improving the generation and differentiation of induced pluripotent stem cells (iPSCs) for regenerative medicine applications.
View full company profile